OncoDNA is a Belgium-based company founded in December 2012 focusing on precision medicine in oncology.
The company aims to provide cancer molecular profiling to individualize therapy decisions.
The new shares were subscribed by both the historical shareholders (IPG/bio.be, Invest4OncoDNA, Sambrinvest, and Vinsovier) as well as a group of four new investors (Sofinim NV, an affiliate of Ackermans & van Haaren, SRIW, CPH, and Inventures).
[5] In April 2014, OncoDNA was selected for the multi-year analysis research program AURORA conducted by BIG, that aims to significantly improve the life of patients with metastatic or locally relapsed breast cancer.
Initially, 1300 women and men treated in about 60 hospitals spread across 15 European countries are expected to take part in AURORA.